Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.

CONCLUSION: Canakinumab may be an effective treatment option for pediatric FMF patients with colchicine resistance, renal amyloidosis, and chronic oligoarthritis. Further studies are needed to clarify the efficacy of canakinumab in patients with a second disease, RF-positive polyarticular juvenile idiopathic arthritis. PMID: 31463794 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31463794?dopt=Abstract

Source: Paediatric Drugs - August 27, 2019 Category: Pediatrics Authors: Kisla Ekinci RM, Balci S, Dogruel D, Altintas DU, Yilmaz M Tags: Paediatr Drugs Source Type: research